Senior Researcher, SWAN-PI Kirmo Wartiovaara receives 1,1 m€ research funding from the Jane and Aatos Erkko Foundation for Clinical Translation of Gene Editing for Metabolic Diseases.
The project focuses on measuring the effectiveness and safety of gene correction of severe neonatal liver disease ASLD caused by a Finnish genetic defect in a mouse model which the Kirmo Wartiovaara group has created. The research results are the basis for the hospital exemption human use regulatory application. The project involves a societal study of the ethical and legal issues of the novel treatments, as well as the development of hospital practices and training required by the new treatment method.
This research project is an opening in the field of gene editing therapy in Finland, and the Kirmo Wartiovaara group is part of the European working group on the development of academic gene therapy trials.
More details from here.
SWAN congratulates Kirmo for this excellent achievement!